Novo Holdings

Today Novo Holdings portfolio company Invetx announced an agreement to be acquired by Dechra Pharmaceuticals, an international veterinary pharmaceuticals company, for up to $520 million. Novo Holdings co-led Invetx’s Series B financing in 2022, which enabled Invetx to advance its clinical pipeline and pursue market approvals for innovative, protein-based therapeutics targeting chronic and serious diseases in animals.   Novo Holdings is pleased to have supported Invetx in its ongoing journey to transform animal medicine and pioneer the next generation of veterinary care. Learn more about Invetx and this announcement below.

Novo Holdings led a $100 million Series C Financing in Asceneuron, a clinical stage biotech company developing small molecules targeting tau protein aggregation, a driver of neurodegenerative disease. The financing will be used to advance Asceneuron’s lead asset ASN51 into Phase 2 clinical development for the treatment of Alzheimer’s disease.   Alzheimer’s disease is an area of very high unmet medical need with a lack of oral disease modifying therapies. Learn more about Asceneuron and the science behind this therapy below. #ventureinvestments #alzheimers

We are looking for a Junior Analyst to support our activities in our Investment Operations Team. It is a part-time student job, and the role will primarily support our internal procedures, but also on our cash and liquidity management, as well as being an operational support for our investment teams both in private and public trading.

We are looking for a Junior Analyst (student) to join our Planetary Health Investments team. As a Jr. Analyst you will undertake challenging and varying tasks and participate in both investment processes and active ownership of companies within the Planetary Health sector.

Novo Holdings co-led the £90 million ($114 million) Series A financing for London-based Myricx Bio to advance a novel payload class for antibody-drug conjugates (ADCs). Proceeds from the financing will be used to build out Myricx Bio’s proprietary payload platform and advance its pipeline through clinical proof of concept.  Read more about Myricx Bio and its innovative approach below. #ventureinvestments #biotech 

Today, Novo Holdings announced an initial investment in Danish food-tech start-up Matr Foods to support the scaling-up of its production of sustainable meat alternatives.   Established in Copenhagen in 2021, MATR Foods specialises in developing organic innovative plant-based meat alternatives using traditional fungal fermentation techniques. The Company’s flagship product, MATR Fungi Mince, has an amino acid profile like meat, but with a carbon footprint of just 1.4 kg CO2 e per kg, which is 94% lower than that of beef.

The Novo Holdings Boston office received its official Best Place to Work award from the Boston Business Journal. In this employee-led award nomination, Novo Holdings stood out for its purpose driven, collaborative workplace, and its employee benefit package. “Novo Holdings is entirely owned by a philanthropic and non-profit organization, the Novo Nordisk Foundation. Knowing that the returns of our investments are funneled back to the Foundation to advance research in medical science and sustainability for the planet is highly inspiring for all of us in Boston,” said Abhijeet Lele, Senior Partner, Head of Principal Investments US. #workplace #culture

We are seeking an experienced Corporate Event Specialist to join our team at Novo Holdings in Copenhagen. Novo Holdings is expanding in team and presence, fostering a need for a dedicated event planner to strengthen our internal culture and external relationships through impeccable event experiences.

Novo Holdings and DLG Group are pleased to announce a strategic partnership to advance sustainable agriculture and food systems, with Novo Holdings acquiring 25% of Sejet Plant Breeding (Sejet), a leader in agricultural innovation owned by DLG Group.   Since 1947, Sejet has excelled in developing essential genetics of field crops like wheat and barley, enhancing productivity with fewer resources. Leveraging innovative breeding technologies, Sejet focuses on creating crop varieties that are robust, productive, and sustainable.   The partnership aims to scale Sejet’s operations, invest in new technologies, and boost market share in Europe, driving forward agricultural innovation and sustainability. Read more: https://lnkd.in/dpZr4ENH

We are looking for an experienced Head of Accounting to contribute to Novo Holdings and Novo Nordisk Foundation’s ambitious journey to shape future health, societal sustainability, and planetary wellbeing. As Head of Accounting, you will be pivotal in driving the day-to-day operations and strategic direction of the accounting services for the Novo Nordisk Foundation and various Novo Nordisk Foundation group entities through Service Line Agreements. Moreover, you will be responsible for establishing and driving the procurement function within Novo Holdings.